HighTower Advisors
SVA

HighTower Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

HighTower Advisors’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-45,925
Closed -$259K – 1731
2014
Q2 		$259K Hold
45,925
– – ﹤0.01% 1306
2014
Q1 		$331K Buy
45,925
+2,275
+5% +$15.1K 0.01% 1129
2013
Q4 		$267K Buy
+43,650
New +$263K 0.01% 1197

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

HighTower Advisors's SVA Position: Q3 2014 in Review

HighTower Advisors sold out of Sinovac Biotech, Ltd (SVA) in Q3 2014, closing a stake of 45,925 shares — an estimated $259K sold.

HighTower Advisors first reported a position in SVA in Q4 2013 and held it in 3 quarters. The position peaked at $331K in Q1 2014. 45 funds tracked by Wall St. Rank hold SVA as of Q3 2014.

  • HighTower Advisors reported no remaining Sinovac Biotech, Ltd position as of Q3 2014 after selling out during the quarter.
  • HighTower Advisors sold 45,925 Sinovac Biotech, Ltd shares in Q3 2014, an estimated $259K.
  • HighTower Advisors first reported a position in Sinovac Biotech, Ltd in Q4 2013 and held it in 3 quarters.
  • HighTower Advisors's Sinovac Biotech, Ltd position peaked at $331K in Q1 2014.
  • 45 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2014.

Based on HighTower Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.